( Epub 2021 Aug 17 PMID: 34403495 ) Vallatharasu Y, Hayashi-Tanner Y, Polewski PJ, Bottner WA, Rosenstein LJ, Uprety D, Bista A, Farnen JP, Aster R (2019) Severe, prolonged thrombocytopenia in a patient sensitive to exenatide
Dosing and Protocol Mistakes Starting Too High: Beginners sometimes start with aggressive doses of 1 mg or higher based on the assumption that more is better
In response to the explosion of the unregulated peptides market, the MHRA, the body responsible for licensing and overseeing the use of medicines in the UK, says that it does not "accept attempts to evade medicines regulation" by selling peptides for "research purposes" where evidence indicates they are being used by people
A Quick Overview Before we get into the secrets, lets establish some context